Invention Grant
- Patent Title: Biomarker SPAG5
-
Application No.: US15417511Application Date: 2017-01-27
-
Publication No.: US10775381B2Publication Date: 2020-09-15
- Inventor: Graham Roy Ball , Stephen Yan Tat Chan , Tarek Mohamed Ahmed Abdel-Fatah
- Applicant: Nottingham Trent University , Nottingham University Hospitals NHS Trust
- Applicant Address: GB Nottingham GB Nottingham
- Assignee: NOTTINGHAM TRENT UNIVERSITY,NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST
- Current Assignee: NOTTINGHAM TRENT UNIVERSITY,NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST
- Current Assignee Address: GB Nottingham GB Nottingham
- Agency: Troutman Pepper Hamilton Sanders LLP (Rochester)
- Priority: com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@f94d2e1
- Main IPC: G01N33/574
- IPC: G01N33/574 ; C12Q1/6886 ; C07K16/18 ; G01N33/577 ; C07K16/30

Abstract:
There has been a recent shift in cancer therapy from one size fits all to a personalized and tailored treatment for individual patients to increase efficiency and avoid unnecessary toxicity. This invention relates to a method of determining the prognosis and suitable treatment of cancer in a subject by measuring the level of expression of SPAG5. In particular, it relates to a method where high expression of SPAG5 in tumour cells correlates with aggressive tumours.
Public/Granted literature
- US20170138947A1 Biomarker SPAG5 Public/Granted day:2017-05-18
Information query
IPC分类: